Skip to main content
Top
Published in: Breast Cancer Research 1/2000

01-03-2000 | Meeting abstract

Genetic variants of CYP19 (aromatase) and breast cancer risk

Authors: V Nedelcheva Kristensen, N Harada, N Yoshimura, E Haraldsen, PE Lønning, B Erikstein, R Kåresen, T Kristensen, A-L Børresen-Dale

Published in: Breast Cancer Research | Special Issue 1/2000

Login to get access

Excerpt

The effect of an SNP in exon 10 of CYP19 on tumour mRNA levels and splice variants was studied and correlated with clinical parameters and risk of breast cancer. In the vast majority of breast cancers, the estrogen levels modulate the tumour growth and depend on the activity of CYP19. Patients (n =481) and controls (n =236) were genotyped by T-tracks in a single sequencing reaction (SSR). The frequency of TT genotypes was significantly higher in patients versus controls (P =0.007) particularly among those with stage III and IV disease (P =0.004) and with tumours larger than 5 cm (P =0.001). A significant association between presence of the T allele and the level of aromatase mRNA in the tumours was observed (P =0.018), as well as with a switch from adipose promoter to ovary promoter (P =0.004). Previously, we reported a rare polymorphic allele of CYP19 (repeat (TTTA)12) to be significantly more frequent in breast cancer patients than in controls. Here we describe another polymorphism, a C-T substitution in exon 10 of the CYP19 gene which is in strong linkage disequilibrium with the (TTTA)n polymorphism but with higher frequency of the variant allele. Our data suggest that the T-allele of the CYP19 gene is associated with a `high activity' phenotype. …
Metadata
Title
Genetic variants of CYP19 (aromatase) and breast cancer risk
Authors
V Nedelcheva Kristensen
N Harada
N Yoshimura
E Haraldsen
PE Lønning
B Erikstein
R Kåresen
T Kristensen
A-L Børresen-Dale
Publication date
01-03-2000
Publisher
BioMed Central
Published in
Breast Cancer Research / Issue Special Issue 1/2000
Electronic ISSN: 1465-542X
DOI
https://doi.org/10.1186/bcr153

Other articles of this Special Issue 1/2000

Breast Cancer Research 1/2000 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine